Document Type
Article
Publication Title
Cancer Control
Abstract
Chronic active hepatitis B infection (HBV) has been implicated in lymphomagenesis of non-Hodgkin lymphoma (NHL). Treatment of cancer including NHL with chemotherapy or immunotherapy can lead to HBV reactivation in previously infected patients. Serological testing of HBV prior to initiation of this therapy is recommended by several national and international medical agencies and expert panels. Patients with positive hepatitis B surface antigen (HBsAg) and anti-hepatitis B core antibody (anti-HBc ab) need to start antiviral therapy with entecavir or tenofovir prior to initiation of chemotherapy or immunotherapy and continue this treatment for 6 to 12 months after completion of cancer therapy to avoid late HBV reactivation. Monitoring of HBV DNA viral load and liver function tests should be done during cancer therapy in infected patients. Hepatitis B infection vaccination resulted in decreases prevalence of HBV virus carriers and decreased incidence of virus-induced malignancies.
DOI
10.1177/1073274818767879
Publication Date
1-2018
Keywords
antiviral therapy, chemotherapy, hepatitis B, non-Hodgkin lymphoma, rituximab
ISSN
1526-2359
Recommended Citation
Kelling M, Sokol L, Dalia S. Hepatitis B Reactivation in the Treatment of Non-Hodgkin Lymphoma. Cancer Control. 2018; 25(1). doi: 10.1177/1073274818767879.
